Research programme: MAPK pathway modulators - Alterome Therapeutics
Latest Information Update: 17 May 2024
At a glance
- Originator Alterome Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Apr 2024 Preclinical trials in cancer in USA (unspecified route) prior to April 2024, (Alterome Therapeutics pipeline, April 2024)